A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial Tumours
Latest Information Update: 22 Oct 2024
At a glance
- Drugs NG 350A (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma
- Focus Adverse reactions
- Acronyms FORTIFY
- Sponsors Akamis Bio
Most Recent Events
- 08 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2023 Planned End Date changed from 1 Jul 2023 to 23 May 2025.
- 01 Aug 2023 Planned primary completion date changed from 1 Mar 2023 to 17 Mar 2025.